154 related articles for article (PubMed ID: 24327975)
1. Promising treatment results of adjuvant chemotherapy following radical hysterectomy for intermediate risk stage 1B cervical cancer.
Lee TY; Jeung YJ; Lee CJ; Kim HY; Kim SH; Kim WG
Obstet Gynecol Sci; 2013 Jan; 56(1):15-21. PubMed ID: 24327975
[TBL] [Abstract][Full Text] [Related]
2. [Prognostic analysis of stage Ⅰb2 andⅡa2 cervical squamous cancer without high risk factors treated with neo-adjuvant chemotherapy and radical hysterectomy].
Li PP; Li B; Wang YT; Liu SH; Zhang YN; Zhang R; Bai P; Li XG; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2018 Apr; 53(4):248-256. PubMed ID: 29747270
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of chemotherapy as monotherapy in patients with recurrent intermediate/high-risk factors following radical hysterectomy for stage IB-IIA cervical cancer: a single-center retrospective analysis.
Dong B; Zhou SF
BMC Womens Health; 2024 May; 24(1):297. PubMed ID: 38762459
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy versus radiotherapy for FIGO stages IB1 and IIA1 cervical carcinoma patients with postoperative isolated deep stromal invasion: a retrospective study.
Li L; Song X; Liu R; Li N; Zhang Y; Cheng Y; Chao H; Wang L
BMC Cancer; 2016 Jul; 16():403. PubMed ID: 27387204
[TBL] [Abstract][Full Text] [Related]
5. Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
Lee HN; Lee KH; Lee DW; Lee YS; Park EK; Park JS
Int J Gynecol Cancer; 2011 Jan; 21(1):128-36. PubMed ID: 21330837
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors affecting the outcome of early cervical cancer treated with radical hysterectomy and post-operative adjuvant therapy.
Liu MT; Hsu JC; Liu WS; Wang AY; Huang WT; Chang TH; Pi CP; Huang CY; Huang CC; Chou PH; Chen TH
Eur J Cancer Care (Engl); 2008 Mar; 17(2):174-81. PubMed ID: 18302655
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study).
Nakamura K; Kitahara Y; Satoh T; Takei Y; Takano M; Nagao S; Sekiguchi I; Suzuki M
World J Surg Oncol; 2016 Jun; 14(1):173. PubMed ID: 27356862
[TBL] [Abstract][Full Text] [Related]
8. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage IB-IIA cervical cancer.
Takeshima N; Umayahara K; Fujiwara K; Hirai Y; Takizawa K; Hasumi K
Gynecol Oncol; 2006 Nov; 103(2):618-22. PubMed ID: 16777200
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma.
Hiura M; Nogawa T; Matsumoto T; Yokoyama T; Shiroyama Y; Wroblewski J
Int J Gynecol Cancer; 2010 Aug; 20(6):1000-5. PubMed ID: 20683408
[TBL] [Abstract][Full Text] [Related]
10. [Results of different postoperative adjuvant therapies for stage Ib-IIa cervical carcinoma with risk factors].
Wen HW; Huang WP; Liu TY; Ma K; Tao X; Zhu LR; Liao QP
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):920-4. PubMed ID: 24495686
[TBL] [Abstract][Full Text] [Related]
11. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
[TBL] [Abstract][Full Text] [Related]
12. The upper limit of optimal tumor size in patients with FIGO 2018 stage IB2 cervical cancer undergoing radical hysterectomy.
Hwang WY; Kim JH; Suh DH; Kim K; No JH; Kim YB
Int J Gynecol Cancer; 2020 Jul; 30(7):975-980. PubMed ID: 32467336
[TBL] [Abstract][Full Text] [Related]
13. Can chemotherapy boost the survival benefit of adjuvant radiotherapy in early stage cervical cancer with intermediate risk factors? A population based study.
Mahmoud O; Hathout L; Shaaban SG; Elshaikh MA; Beriwal S; Small W
Gynecol Oncol; 2016 Dec; 143(3):539-544. PubMed ID: 27769525
[TBL] [Abstract][Full Text] [Related]
14. Chemoradiotherapy is not superior to radiotherapy alone after radical surgery for cervical cancer patients with intermediate-risk factor.
Kim H; Park W; Kim YS; Kim YJ
J Gynecol Oncol; 2020 May; 31(3):e35. PubMed ID: 31912685
[TBL] [Abstract][Full Text] [Related]
15. CLPTM1L expression predicts recurrence of patients with intermediate‑ and high‑risk stage IB‑IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy.
Awazu Y; Fukuda T; Noda T; Uchikura E; Nanno S; Imai K; Yamauchi M; Yasui T; Sumi T
Oncol Lett; 2023 Aug; 26(2):353. PubMed ID: 37545614
[TBL] [Abstract][Full Text] [Related]
16. Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stage IB-IIA cervical cancer.
Lee KB; Lee JM; Ki KD; Lee SK; Park CY; Ha SY
Int J Gynecol Cancer; 2008; 18(5):1027-31. PubMed ID: 18021218
[TBL] [Abstract][Full Text] [Related]
17. The issues regarding postoperative adjuvant therapy and prognostic risk factors for patients with stage I-II cervical cancer: A review.
Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
J Obstet Gynaecol Res; 2017 Apr; 43(4):617-626. PubMed ID: 28190285
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
[No Abstract] [Full Text] [Related]
19. [Long-term oncological outcomes after laparoscopic versus abdominal radical hysterectomy in stage I a2- II a2 cervical cancer: a matched cohort study].
Wang W; Shang C; Huang J; Chen S; Shen H; Yao S
Zhonghua Fu Chan Ke Za Zhi; 2015 Dec; 50(12):894-901. PubMed ID: 26887872
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer.
Matsuo K; Shimada M; Yokota H; Satoh T; Katabuchi H; Kodama S; Sasaki H; Matsumura N; Mikami M; Sugiyama T
Oncotarget; 2017 Dec; 8(63):106866-106875. PubMed ID: 29290995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
